European Countries Flags Four Medicines For Joint HTA Evaluation
Executive Summary
Drugs for treating Duchenne muscular dystrophy and amyotrophic lateral sclerosis are among the products that the European cross-country coalition BeNeLuxA thinks would be suitable for a joint health technology evaluation.
You may also be interested in...
Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.
Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
Brazilian Regulator Extends COVID-19 Measures
Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.